Submit investigational new drug application for intranasal SPC-15
Not delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 2 Jan 2025
- Due
- 31 Dec 2025
- Checked
- 11 Sep 2026
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“expected IND submission in 2025, followed by a Phase 1 clinical trial in PTSD upon approval”
What we found
Evidence strength A What the grades mean
Silo Pharma did not submit the SPC-15 IND by end of 2025 as promised; company statements shifted the target to 2026, with preclinical/CMC work still ongoing as of June 2026.
-
A Silo Pharma, Inc. - Form S-1 - FY2025 SEC filing states company is 'aiming for an IND submission in 2026,' not 2025.
-
B Silo Pharma Issues Update on Milestone Achievements in PTSD Drug Development Late October 2025 update says IND-enabling GLP study data expected in 2026, still pre-submission.
-
B Silo Pharma Partners with Allucent to Support Planned FDA IND Application for SPC-15 As of mid-November 2025, IND application was still only 'planned,' not yet submitted.
-
D Planned FDA Investigational New Drug Application: SPC-15 for the Treatment of PTSD States Silo Pharma currently expects to submit the IND in 2026, revising earlier 2025 timeline.
Checked 11 Sep 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Regulatory submission
- Indicative materiality
- High rules
- Action
- Submit
- Language
- Expected (“expects”, “plans”)
- Conditional
- Yes
How this entry was checked
- Commitment recordedRecorded from the company's filing.
- First checkAn AI model read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Gemini (Google), re-read the evidence without being told the outcome and reached the same answer.
- Third check on a negative finding: agreesBecause a negative finding could harm a company if wrong, a stronger model re-read the evidence fully blind and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Silo Pharma, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2025-SILO-000006 · Corrections policy